Organisation profile

We are studying the role of prolyl oligopeptidase (PREP, formerly known as POP) on disease progression and neuronal toxicity in neurodegenerative disorders with protein aggregation. These disorders involve several serious diseases such as Alzheimer’s and Parkinson’s diseases, and several more rare neurodegenerative conditions. Based on PREP inhibitors, we are developing novel and disease-modifying drug therapies to stop the neuronal death in Alzheimer's and Parkinson's diseases.

Read more on our website

International and National Collaboration

Publications and projects within past five years.